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Abstract
Background: D‐dimers are generated during endogenous fibrinolysis of a blood clot 
and have a central role in diagnostic algorithms to rule out venous thromboembolism. 
HMG‐CoA reductase inhibitors, more commonly called statins, are known to have 
effects independent of LDL‐cholesterol lowering, including antithrombotic proper-
ties. An effect of statins on D‐dimer levels has been reported in a prior systematic 
review and meta‐analysis, but methodological shortcomings might have led to an 
overestimated effect. To re‐evaluate the association between statins and D‐dimer 
levels, we systematically reviewed all published articles on the influence of statins 
on D‐dimer levels and conducted a novel meta‐analysis (PROSPERO registration 
number CRD42017058932).
Materials and methods: We electronically searched EMBASE, Medline Epub, 
Cochrane, Web of Science and Google Scholar (100 top relevance) (date of last 
search: 5 October 2017). We included randomized controlled trials, cohort studies 
and cross‐sectional studies. Two reviewers independently screened all articles re-
trieved and extracted data on study and patient characteristics, study quality and D‐
dimer levels.
Results: Study‐level meta‐analysis involving 18,052 study participants showed 
lower D‐dimer levels in those receiving statin treatment than controls (SMD: −0.165, 
95% CI −0.234; −0.096, P = <0.001). Sensitivity analyses and additional analyses 
on treatment duration (<12 weeks vs ≥12 weeks) and type of statin (lipophilic or 
hydrophilic) did not modify this overall result.
Conclusion: This meta‐analysis suggests an association between use of statins and 
reduction of D‐dimer levels, independent of treatment duration and type of statin 
used. This effect is small but robust, and should be interpreted with caution.
K E Y W O R D S
D‐dimer, fibrin fragment D, hydroxymethylglutaryl‐CoA reductase inhibitors, meta‐analysis, venous 
thromboembolism
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1 |  INTRODUCTION
In case of a thromboembolism, D‐dimers are generated in 
the blood clot during fibrinolysis by the sequential action 
of thrombin, activated factor XIII and plasmin.1,2 Age, ac-
tive malignancy, infection, pregnancy and use of antico-
agulants are well known to have an influence on D‐dimer 
levels.3-6 Use of medication with an effect on thrombus 
formation, such as HMG‐CoA reductase inhibitors, more 
commonly known as statins, may influence D‐dimer lev-
els as well. These antithrombotic properties are part of 
what has been referred to as the cholesterol‐independent 
or “pleiotropic” effects of statins, explaining why the ben-
efits observed with statins appear to exceed what might 
be expected from changes in cholesterol levels alone.7-9 
In line with these antithrombotic effects, statin treatment 
might lead to a 15% lower risk of primary venous throm-
bosis as confirmed in a recent meta‐analysis of interven-
tion studies.7
In clinical practice, D‐dimer levels have a central role 
in diagnostic algorithms to rule out venous thromboem-
bolism (VTE).10,11 Several studies have addressed the ef-
fect of statins on D‐dimer levels, with some of them being 
evaluated in a systematic review and meta‐analysis by 
Sahebkar et al12 This meta‐analysis included nine random-
ized controlled trials and reported a significant reduction 
of 0.988 µg/mL (95%CI: −1.590 to −0.385, P = 0.001) in 
D‐dimer levels in statin users. However, this estimate is in-
appropriate since the used Cohen's d effect size should be 
dimensionless, while 0.988 µg/mL suggests a tremendous 
clinical impact of statin use on D‐dimer levels. Triggered 
by this inaccuracy, we further elucidated the used methods 
and results and found several important shortcomings. Our 
main concerns next to misuse of Cohen's d are incorrect 
extraction of data from original studies and unreported 
assumptions.
Because the research question is of high importance 
though, we decided to conduct a novel systematic review and 
meta‐analysis on the effect of statins on D‐dimer levels, in-
cluding recent studies.
2 |  METHODS
2.1 | Protocol registration
This study was registered on 10 March 2017 in the 
PROSPERO international prospective register of system-
atic reviews (CRD42017058932) and designed according 
to the guidelines of the 2009 Preferred Reporting Items for 
Systematic Reviews and Meta‐Analysis (PRISMA) state-
ment (Appendix S1 and S2).13
2.1.1 | Search methods for 
identification of studies
Together with a biomedical information specialist (see 
Acknowledgement), SS‐G electronically searched the fol-
lowing databases: EMBASE (Ovid SP); Medline Epub 
(Ovid SP); Cochrane Central Register of Controlled Trials 
(CENTRAL); Web of Science and Google Scholar (100 top 
relevance) (date of last search: 5 October 2017). We used 
search terms as reported in “Appendix S3,” in summary: 
D‐dimer OR D‐dimers AND statin OR statins OR hydroxy-
methylglutaryl reductase OR HMG‐CoA reductase in com-
bination with individual drug names of statins. To improve 
sensitivity, we also combined these search terms with the 
wild‐card term “*” and the accessory MeSH terms.
2.2 | Data collection and extraction process
Two authors (SS‐G and FM) independently screened titles and 
abstracts retrieved by the electronic survey, and disagreement 
in selection was resolved by discussion. After consensus was 
reached, the two reviewers independently selected eligible 
articles based on the results in full text. Selection of articles 
was discussed in detail, and in case of disagreement, a third 
author (TvG) was consulted for final decision. We present a 
flow diagram to show the decision‐making process for in-
cluding studies in the review (Figure 1).13 The first reviewer 
(SS‐G) extracted the following data: first author's name, year 
of publication, study design, country where the study was 
performed, D‐dimer assay used, use of co‐medication, num-
ber of participants, time of exposure, statin regimen, D‐dimer 
levels with its variation and the conclusions of the individual 
studies on the effect of statins on the D‐dimer levels. Also, 
all QUADAS‐2 items were assessed. If results could not be 
extracted from original articles (table or well described in the 
text), authors were requested repeatedly to send their original 
data. All D‐dimer levels were converted to µg/mL. If multiple 
D‐dimer levels were available, we chose to report those values 
close to 6‐month follow‐up. All results after extraction were 
double‐checked and confirmed by the second reviewer (FM).
2.3 | Selection of studies
We included randomized controlled trials, cohort studies 
and cross‐sectional studies conducted in humans, in which 
D‐dimers levels were described or reported and results 
could be compared among users or nonusers of statins. For 
both randomized controlled trials and cohort studies, we de-
fined that statins should be used for at least 7 days in order 
to achieve a pharmacodynamically relevant effect.14,15 
Also, to prevent interference of the effect of anticoagulant 
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drugs on D‐dimer levels, we excluded randomized con-
trolled trials or cohorts primary conducted among patients 
treated with anticoagulant drugs at baseline or during fol-
low‐up. Studies in which any medical intervention or car-
diovascular event within 2  months between baseline and 
follow‐up measurement of D‐dimer levels was part of the 
inclusion criteria were also excluded to reduce confound-
ing effects on D‐dimer levels. Since different D‐dimer tests 
are used in clinical practice, we decided to include only 
standardized enzyme‐linked immunoassays or latex (semi) 
quantitative tests.16 Studies without availability of full text 
that were also not available after repeated requests to the 
(corresponding) authors or articles not written in English 
language were excluded, because the quality of these arti-
cles could not be assessed.
2.4 | Risk of bias in individual studies and 
across studies
The data extraction form incorporated a quality assess-
ment section comprising items from Quality Assessment of 
F I G U R E  1  Flow diagram on decision‐making process for including studies following PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta‐Analyses) statement
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Diagnostic Accuracy Studies‐2 (QUADAS‐2).17 Following 
this revised tool, we omitted and added signalling questions 
and two independent reviewers (SS and FM) applied the 
QUADAS‐2 score in a small number of studies. After refine-
ment of the tool (as described in detail in Appendix S4) with 
review‐specific signalling questions and appropriate items, 
grouped into three domains (patient selection, index test, and 
flow and timing) also scoring conflicts of interest, we applied 
this tool for all studies. We evaluated the influence of each 
study on the overall effect size by removing one study each 
time and repeating the analysis, a so‐called leave‐one‐out 
method sensitivity analysis.18 We also performed a subanaly-
sis including only studies with low‐risk patient selection bias 
and low concern about applicability according to the scoring 
of these QUADAS‐2 items and performed a separate suba-
nalysis only including controlled trials. To detect potential 
publication bias, we visually inspected the distribution of the 
studies within a funnel plot and also created a funnel plot 
taking into account the trim‐and‐fill adjustment of Duval and 
Tweedie.19 Also, Begg's rank correlation and Egger's test 
were used to detect publication bias.20,21 Furthermore, as an-
other marker of publication bias, we estimated the number of 
missing studies we would need to retrieve and impute in the 
meta‐analysis to make the p‐value nonsignificant using the 
“fail‐safe N” method.22
2.5 | Quantitative data‐synthesis
The meta‐analysis was conducted using Comprehensive 
Meta‐analysis (version 3; Biostat). In studies in which 
participants were exposed to different statin regimens, the 
different statin‐exposed groups were analysed separately 
and values were compared to the control group in case of 
(randomized) controlled studies. When medians and in-
terquartile ranges (IQR) were reported, we estimated the 
average standard deviation (SD) using the following for-
mula: SD = ((75th percentile‐25th percentile)/1.35) and in 
case of reporting medians and full range, we estimated the 
average SD using the following formula: SD = ((75th per-
centile‐25th percentile)/5.16).23 If not reported, the mean 
difference was estimated using the following formula: SD 
= square root [(SDpre‐treatment)2 + (SDpost‐treatment)2 
− (2R × SDpre‐treatment × SDpost‐treatment)], assuming 
a correlation coefficient (R) = 0.5. Net changes in meas-
urements (change scores) were calculated for controlled 
trials, as follows: (value at end of follow‐up in the treat-
ment group − value at baseline in the treatment group) − 
(value at end of follow‐up in the control group − value 
at baseline in the control group). If percentage change in 
D‐dimer levels was reported, we estimated mean or me-
dian D‐dimer post‐treatment levels by multiplying reported 
mean or median pre‐treatment D‐dimer levels with 1 + 
percentage change and assumed that the post‐treatment SD 
was equal to reported SD before treatment. For crossover 
studies, we used the reported results of delta mean change 
and its corresponding SD to prevent artificial widening of 
confidence intervals of the pooled treatment effect.24 For 
cohorts, we calculated change scores by (value at end of 
follow‐up in the treatment group − value at baseline in the 
treatment group) assuming that in a fictional control group 
D‐dimer would not change during follow‐up. For results 
on cross‐sectional studies, we measured change scores by 
(value in the statin users group − value in the nonexposed 
group). When the authors adjusted D‐dimer levels for other 
confounding factors, we used the adjusted D‐dimer levels 
for analysis. We expressed effect sizes as a standardized 
mean difference (SMD) with its corresponding 95% con-
fidence intervals (CIs) using the dimensionless Cohen's d 
as the summary statistic.25 To compensate for heterogene-
ity including study design, population characteristics, sta-
tin dose and treatment duration, we used a random‐effects 
model. Post hoc subanalyses were performed to assess the 
potential effects of treatment duration of statin therapy 
(<12 weeks vs ≥12 weeks) and type of statin (lipophilic 
or hydrophilic). Simvastatin, atorvastatin and fluvastatin 
were classified as lipophilic statins and pravastatin and ro-
suvastatin as hydrophilic statins.15
3 |  RESULTS
3.1 | Study selection and evaluation of bias 
of individual studies
In total, we screened 307 studies, of which 60 were assessed 
for eligibility reading full text, and finally, 22 studies were 
included in this review (Figure 1).26-47 Reasons for exclusion 
were an event or intervention <2 months (n = 4), not written in 
English (n = 3), no specific D‐dimer data available on baseline 
or follow‐up (n = 18), nonstandardized D‐dimer measurement 
(n = 2), no original research article (n = 9) and repeated analy-
sis on same data set (n = 2). We included 7 controlled trials, 
11 cohort studies and 4 cross‐sectional studies. Taken together, 
this analysis included 22 control groups and 27 statin‐exposed 
groups with a total number of 18 052 study participants (Table 
1). The included studies were performed among different study 
populations. Six studies were performed in subjects with dys-
lipidaemia, 6 studies in patients with proven cardiovascular 
disease, 4 studies in HIV‐infected patients, 2 in patients with 
type 2 diabetes mellitus, one in healthy subjects, one in patients 
diagnosed with lupus, one in COPD patients and one in heart 
transplant patients. Of all 27 statin‐exposed groups, 17 groups 
were defined as lipophilic‐type statin users and 7 as hydro-
philic‐type statin users, while the other 3 groups comprised of 
lipophilic‐type as well as hydrophilic‐type statin users. Of the 
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23 statin‐exposed groups in which we could assess treatment 
duration, 19 groups were exposed to statins for 12 weeks or 
longer.
The risk of bias regarding patient selection was regarded 
low for only 6 of the 22 included studies and for 8 studies 
we had concerns about applicability of the results based on 
the specific characteristics of the statin‐exposed groups and 
control groups included in these studies (Figure 2, Table S1). 
For four studies, the D‐dimer test was not clearly described, 
and we assumed a standardized test.34,37,38,47
3.2 | Meta‐analysis
Study‐level meta‐analysis involving 18 052 study participants 
showed significantly lower D‐dimer levels in those receiving 
statin treatment compared to controls (SMD: −0.165, 95% 
CI −0.234; −0.096, P ≤ 0.001) (Figure 3). The estimated ef-
fect sizes were similar in sensitivity analyses that omitted any 
single study (Figure 4). The 6 studies with low risk of patient 
selection (SMD: −0.099, 95%CI −0.140; −0.058, P < 0.001) 
and the 16 studies with low risk of limited patient applicabil-
ity (SMD: −0.216, 95%CI −0.334; −0.099, P < 0.001) also 
resulted in lower D‐dimer values after statin treatment. A 
separate meta‐analysis of the 7 controlled trials did not show 
a different effect on D‐dimer levels (SMD: −0.096, 95% CI 
−0.138; −0.055, P  <  0.001). Furthermore, treatment dura-
tion (<12 weeks vs ≥12 weeks) did not influence the effect 
on D‐dimer levels in statin users (P = 0.887) (Figure 5) and 
type of statin (lipophilic or hydrophilic) also did not modify 
this overall result (P = 0.167) (Figure 6).
3.3 | Publication bias
A visual inspection of the funnel plot showed asymmetry, 
suggesting potential publication bias. Using the “trim‐and‐
fill” method with five potentially missing studies imputed, 
the effect size was estimated to an adjusted SMD with a 
larger effect (−0.224, 95% CI −0.295; −0.153) than the un-
adjusted SMD (Figure 7). Begg's rank correlation (Kendall's 
Tau with continuity correction  =  −0.160, Z  =  1.167, two‐
tailed P = 0.243) and Egger's test (intercept −0.611, 95% CI 
−1.447; 0.226, two‐tailed P = 0.145) were both nonsignifi-
cant. Following the “fail‐safe N” method, we would need to 
retrieve and impute 422 missing studies in the meta‐analysis 
to make the p‐value nonsignificant.
4 |  DISCUSSION
In this meta‐analysis, for which we included randomized con-
trolled trials, cohort and cross‐sectional studies conducted in 
humans, we found that statin treatment is associated with 
lower D‐dimer levels. This effect is small but robust and not 
driven by any single study. Results from post hoc subanaly-
ses on treatment duration and type of statin therapy were not 
different from this overall effect.
Our findings are important in further understanding the 
pleiotropic antithrombotic effects of statins. Statins have 
been shown to significantly lower the risk of primary VTE 
and therefore might have a role in the prevention of VTEs.7,48 
Several mechanisms have been described to explain these 
antithrombotic properties. Statins inhibit platelet activation 
within hours after intake by upregulation of the nitric oxide 
synthase and downregulation of phospholipase A2–mediated 
thromboxane A2 formation and probably also by reduced 
exposure of platelet‐derived microparticles and glycoprotein 
IIIa, a receptor for fibrinogen and von Willebrand factor.49-51 
Also important, statins interfere directly with the clotting 
system. In vitro, two lipophilic types of statins decreased 
tissue factor activity in a dose‐dependent manner.52 As a re-
sult, a smaller amount of factor X is activated and generation 
of thrombin is diminished.8,53,54 Other ways through which 
statins interfere with the clotting system are inhibition of 
isoprenoid intermediates, which indirectly activates the pro-
tein C pathway and lowering of the oxidized LDL‐induced 
tissue factor expression. Inhibition of geranylgeranylation of 
the Rho/Rho kinase pathway is one of the key mechanisms 
of these anticoagulant effects.8,55 By inhibition of this path-
way, resulting in a shift in the fibrinolytic balance towards 
increased fibrinolytic activity is suggested by inhibition of 
the expression of plasminogen activator inhibitor‐1 and up-
regulation of tissue‐type plasminogen activator.56,57
These mechanisms might consequently result in lower D‐
dimer levels in statin users. This decrease of D‐dimer levels 
may theoretically be stronger for lipophilic than for hydro-
philic type of statin users. Lipophilic type of statins can 
enter cells in any organ and also penetrate cell membranes. 
In contrast, cellular uptake of hydrophilic type of statins is 
dependent on the presence of a specific carrier‐mediated 
mechanism, which is only present in hepatocytes but not in 
extrahepatic cells.58 Furthermore, tissue factor activity could 
in vitro only be decreased by lipophilic type of statins and not 
by pravastatin, a hydrophilic type of statin.52 Clinical relevant 
difference of pleiotropic effects in general between lipophilic 
and hydrophilic type of statins is however controversial.9 In 
our subanalyses on type of statin therapy, for both lipophilic 
and hydrophilic type of statin users D‐dimer levels were sig-
nificantly lower. This effect was not significantly different 
among these groups. Probably the clinical anticoagulant ef-
fect in vivo is independent on the mechanism of uptake.
The question of a possible dose‐effect of statins in lower-
ing D‐dimer levels is also relevant, yet hard to answer because 
of difference in statin types and dosages that were applied 
in the included studies. Still, we applied a post hoc analy-
sis, utilizing the previously developed concept of a “statin 
6 of 15 |   SCHOL‐GELOK Et aL.
T A B L E  1  Characteristics of included studies for meta‐analysis on the effect of statins on plasma D‐dimer level
  Location Population D‐dimer assay
Information about use 
of co‐medication Age (years) Time of exposure Regimen (daily dose)
Participants 
(number)
D‐dimer (µg/mL) 
before exposure
D‐dimer (µg/mL) after 
exposure Conclusion Details
Controlled trials
Chang, 2002 South Korea Haemodialysis 
patients with 
hypercholesterolaemia5
ELISA Asserachrom D‐Di 
(Diagnostica Stago, Asnières‐
sur‐Seine, France)
Exclusion cholesterol 
modifying or oxidation 
medication
63 (11) 
60 (12)
8 wk Simvastatin (20mg) 
No simvastatin
28 
30
1.05 (0.90) 
1.12 (1.01)
0.99 (0.83) 
1.09 (0.97)
No effect Open RCT
Eckhard, 2014 USA Nonhypercholesterolaemic 
HIV infected
LPIA (Diagnostica Stago, 
Parsippany, NJ)
On antiretroviral 
therapy ASA, steroids, 
NSAIDs, antihyperten-
sive medication
45.6 
(41.1‐51.4) 
46.9 
(39.2‐53.6)
24 wk Rosuvastatin (10 mg) 
Placebo
67 
69
0.19(0.13‐0.33) 
0.18 (0.09, 0.29)
Baseline + 6.9% (43.8 
to −35.0) 
Baseline + 21.9% 
(−9.1 to 73.3)
No effect Double‐blind RCT
Kinlay, 2009 USA acute coronary syndromes Not reported ASA, heparin, nitrates 
and β‐blockers
64 (12) 16 wk Atorvastatin (80 mg) 
Placebo
387 Overall 0.3447 (0.0708 
to 5.351)
Baseline + 0.0108 µg/
mL (−93,2 to 145) 
Baseline + 0.0244 µg/
mL (−0.1097 to 
0.1234)
No effect Double‐blind RCT
Nixon, 2016a USA HIV infected ELISA (Diagnostica Stago, 
Asnières‐sur‐Seine, France)
On antiretroviral therapy 
Exclusion of immuno-
suppressant users
48 (41‐55) 20 wk a)Atorvastatin (10‐20 mg) 
a)Placebo 
b)Placebo 
b)Atorvastatin (10‐20mg)
37 
37 
36 
36
0.1870 (0.1209‐0.3196)
0.1998 (0.1319‐0.3383) 
0.1785 (0.1256‐0.2545) 
0.1727 (0.1212‐0.3039)
0.219 (0.1352‐0.3177) 
0.2127 (0.1467‐0.3393) 
0.1804 (0.1316‐0.2250) 
0.1755 (0.1113‐0.2387)
No difference Double‐blind RCT with crossover 
design with 4‐wk washout period
Sommeijer, 2004 The Netherlands Type 2 diabetes mellitus LPIA (bioMérieux, Durham, 
NC)op
Antihypertensive medi-
cation, ASA
Overall: 59 
(54‐64) 
median 
(IQR)
8 wk Pravastatin (40 mg) 
No pravastatin
50 
50
‐ Between pravastatin and 
no pravastatin group 
change: −0.02 (−0.09 
to 0.05)
No effect Open RCT met crossover design.
Tonkin, 2015 Australia Acute coronary syndrome LPIA (Architect c8000, Abbott 
Diagnostics)
ASA 62 (55‐67) 
63 (56‐68)
12 mos Pravastatin (40mg) 
Placebo
3941 
3922
0.172 (0.112‐0.269) 
0.173 (0.112‐0.276)
0.166 (0.108‐0.263) 
0.178 (0.115‐0.284)
Significant reduction Double‐blind RCT
Van de Ree, 2003 The Netherlands Type 2 diabetes mellitus ELISA (Dade‐Behring, 
Marburg, Germany)
‐ 59.7 (7.6) 
60.3 (7.8) 
58.6 (7.5)
30 wk a)Atorvastatin (10 mg) 
b)Atorvastatin (40‐80 mg) 
Placebo
69 
66 
61
0.115 (0.086‐0.160) 
0.137(0.104‐0.186) 
0.123 (0.101‐0.151)
Baseline −7.4% 
Baseline −8.5% 
Baseline + 1.9%
Significant reduction 
in both atorvastatin 
groups
Double‐blind RCT
Cohort studies
Bolaman, 2006 Turkey Primary 
hypercholesterolaemia
ELISA (not otherwise specified) ‐ 55 (10) 24 wk Atorvastatin (10mg – 20mg) 44 0.195(0.073) 0.197 (0.085) No effect  
Calza, 2017 Italy HIV‐1 infected ELISA (Medical Systems, 
Genova, Italy)
On antiretroviral therapy 
Exclusion of steroid, 
androgen, oestrogen, 
growth hormone, 
antihypertensive medi-
cation, thyroid prepara-
tion and acid‐reducing 
agent users
46.8 
(40.6‐55.9)
6 mos rosuvastatin (10mg) 57 0.345 (0.166‐0.445) 0.275 (0.149‐0.381) Significant reduction  
Costejon, 2017 Spain Females with sae systemic 
lupus erythematosus
Not reported Antimalarials and 
immunosuppressant
47 (23‐80) 8 wk Atorvastatin (20mg) 37 0.49 (0.46) 0.51 (0.39) No effect  
Hölschermann, 
2000
Germany heart transplant re-
cipients receiving oral 
immunosuppression
ELISA (Asserachrom; 
Boehringer Mannheim 
Diagnostics, Mannheim, 
Germany)
immunosuppresssants 48 (12)
(mean 
(SD))
7 d or 1 mos Simvastatin (10mg) 15 0.695 (total range 
0.160‐1.580)
0.490 (total range 
0.160‐1.470)
Significant reduction  
Joukhadar, 2001 Austria Hypercholesterolaemia ELISA (Diagnostica Stago, 
Asnières, France)
Exclusion of hypoli-
paemic, anticoagulant, 
anti‐inflammatory 
or antihypertensive 
medication users
55 (9) 
52 (9) 
55 (8)
3 mos a) Atorvastatin (10 mg) 
b) Pravastatin (40 mg) 
c) Simvastatin (40 mg) 
Pooled data
24 
24 
27 
75
0.42 (0.53) 
0.29 (0.15) 
0.35 (0.25) 
0.35(0.34)
0.35 (0.34) 
0.29(0.16) 
0.33(0.17) 
0.33(0.23)
No effect  
Lin, 2000 Taiwan hypercholesterolaemia LPIA (Diagnostica Stago, 
France)
Antihypertensive 
medication, hormone 
replacement
59.8 (7.1) 8 wk Fluvastatin (40mg) 23 0.38 (0.31) 0.28 (0.19) Significant reduction Exclusion of familial 
hypercholesterolaemia
Lin, 2006 Taiwan hyperlipidaemia LPIA (Diagnostica Stago, 
France)
‐ 58.5 (9.7) 16 wk Simvastatin (20mg‐40mg) 22 0.33 (0.17) 0.29 (0.14) No effect  
Seljeflot, 2002 Norway dyslipidaemia and history 
of angina pectoris
ELISA in plasma and serum 
(Asserachrom D‐Di; Stago 
Diagnostica, Asnières‐sur‐
Seine, France)
Antihypertensive medi-
cation, warfarin, ASA, 
nitrates
Not reported 12 mos a) atorvastatin (20‐40mg) 
b) Simvastatin (20‐40mg)
28 
30
0.493 (0.296‐0.767) 
0.384(0.218‐0.657)
0.416 (0.269‐0.749) 
0.385(0.221‐0.541)
No effect Both serum and plasma D‐dimers 
reported. 
In this review, plasma D‐dimer (mostly 
used assay) reported
Trifiletti, 2003 Italy Hypercholesterolaemia ELISA (Asserachrom; 
Diagnostica Stago)
Exclusion of ASA users 55 (3) 6 mos Atorvastatin (20mg) 32 0.248 (0.055) 0.229 (0.042) No effect  
(Continues)
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T A B L E  1  Characteristics of included studies for meta‐analysis on the effect of statins on plasma D‐dimer level
  Location Population D‐dimer assay
Information about use 
of co‐medication Age (years) Time of exposure Regimen (daily dose)
Participants 
(number)
D‐dimer (µg/mL) 
before exposure
D‐dimer (µg/mL) after 
exposure Conclusion Details
Controlled trials
Chang, 2002 South Korea Haemodialysis 
patients with 
hypercholesterolaemia5
ELISA Asserachrom D‐Di 
(Diagnostica Stago, Asnières‐
sur‐Seine, France)
Exclusion cholesterol 
modifying or oxidation 
medication
63 (11) 
60 (12)
8 wk Simvastatin (20mg) 
No simvastatin
28 
30
1.05 (0.90) 
1.12 (1.01)
0.99 (0.83) 
1.09 (0.97)
No effect Open RCT
Eckhard, 2014 USA Nonhypercholesterolaemic 
HIV infected
LPIA (Diagnostica Stago, 
Parsippany, NJ)
On antiretroviral 
therapy ASA, steroids, 
NSAIDs, antihyperten-
sive medication
45.6 
(41.1‐51.4) 
46.9 
(39.2‐53.6)
24 wk Rosuvastatin (10 mg) 
Placebo
67 
69
0.19(0.13‐0.33) 
0.18 (0.09, 0.29)
Baseline + 6.9% (43.8 
to −35.0) 
Baseline + 21.9% 
(−9.1 to 73.3)
No effect Double‐blind RCT
Kinlay, 2009 USA acute coronary syndromes Not reported ASA, heparin, nitrates 
and β‐blockers
64 (12) 16 wk Atorvastatin (80 mg) 
Placebo
387 Overall 0.3447 (0.0708 
to 5.351)
Baseline + 0.0108 µg/
mL (−93,2 to 145) 
Baseline + 0.0244 µg/
mL (−0.1097 to 
0.1234)
No effect Double‐blind RCT
Nixon, 2016a USA HIV infected ELISA (Diagnostica Stago, 
Asnières‐sur‐Seine, France)
On antiretroviral therapy 
Exclusion of immuno-
suppressant users
48 (41‐55) 20 wk a)Atorvastatin (10‐20 mg) 
a)Placebo 
b)Placebo 
b)Atorvastatin (10‐20mg)
37 
37 
36 
36
0.1870 (0.1209‐0.3196)
0.1998 (0.1319‐0.3383) 
0.1785 (0.1256‐0.2545) 
0.1727 (0.1212‐0.3039)
0.219 (0.1352‐0.3177) 
0.2127 (0.1467‐0.3393) 
0.1804 (0.1316‐0.2250) 
0.1755 (0.1113‐0.2387)
No difference Double‐blind RCT with crossover 
design with 4‐wk washout period
Sommeijer, 2004 The Netherlands Type 2 diabetes mellitus LPIA (bioMérieux, Durham, 
NC)op
Antihypertensive medi-
cation, ASA
Overall: 59 
(54‐64) 
median 
(IQR)
8 wk Pravastatin (40 mg) 
No pravastatin
50 
50
‐ Between pravastatin and 
no pravastatin group 
change: −0.02 (−0.09 
to 0.05)
No effect Open RCT met crossover design.
Tonkin, 2015 Australia Acute coronary syndrome LPIA (Architect c8000, Abbott 
Diagnostics)
ASA 62 (55‐67) 
63 (56‐68)
12 mos Pravastatin (40mg) 
Placebo
3941 
3922
0.172 (0.112‐0.269) 
0.173 (0.112‐0.276)
0.166 (0.108‐0.263) 
0.178 (0.115‐0.284)
Significant reduction Double‐blind RCT
Van de Ree, 2003 The Netherlands Type 2 diabetes mellitus ELISA (Dade‐Behring, 
Marburg, Germany)
‐ 59.7 (7.6) 
60.3 (7.8) 
58.6 (7.5)
30 wk a)Atorvastatin (10 mg) 
b)Atorvastatin (40‐80 mg) 
Placebo
69 
66 
61
0.115 (0.086‐0.160) 
0.137(0.104‐0.186) 
0.123 (0.101‐0.151)
Baseline −7.4% 
Baseline −8.5% 
Baseline + 1.9%
Significant reduction 
in both atorvastatin 
groups
Double‐blind RCT
Cohort studies
Bolaman, 2006 Turkey Primary 
hypercholesterolaemia
ELISA (not otherwise specified) ‐ 55 (10) 24 wk Atorvastatin (10mg – 20mg) 44 0.195(0.073) 0.197 (0.085) No effect  
Calza, 2017 Italy HIV‐1 infected ELISA (Medical Systems, 
Genova, Italy)
On antiretroviral therapy 
Exclusion of steroid, 
androgen, oestrogen, 
growth hormone, 
antihypertensive medi-
cation, thyroid prepara-
tion and acid‐reducing 
agent users
46.8 
(40.6‐55.9)
6 mos rosuvastatin (10mg) 57 0.345 (0.166‐0.445) 0.275 (0.149‐0.381) Significant reduction  
Costejon, 2017 Spain Females with sae systemic 
lupus erythematosus
Not reported Antimalarials and 
immunosuppressant
47 (23‐80) 8 wk Atorvastatin (20mg) 37 0.49 (0.46) 0.51 (0.39) No effect  
Hölschermann, 
2000
Germany heart transplant re-
cipients receiving oral 
immunosuppression
ELISA (Asserachrom; 
Boehringer Mannheim 
Diagnostics, Mannheim, 
Germany)
immunosuppresssants 48 (12)
(mean 
(SD))
7 d or 1 mos Simvastatin (10mg) 15 0.695 (total range 
0.160‐1.580)
0.490 (total range 
0.160‐1.470)
Significant reduction  
Joukhadar, 2001 Austria Hypercholesterolaemia ELISA (Diagnostica Stago, 
Asnières, France)
Exclusion of hypoli-
paemic, anticoagulant, 
anti‐inflammatory 
or antihypertensive 
medication users
55 (9) 
52 (9) 
55 (8)
3 mos a) Atorvastatin (10 mg) 
b) Pravastatin (40 mg) 
c) Simvastatin (40 mg) 
Pooled data
24 
24 
27 
75
0.42 (0.53) 
0.29 (0.15) 
0.35 (0.25) 
0.35(0.34)
0.35 (0.34) 
0.29(0.16) 
0.33(0.17) 
0.33(0.23)
No effect  
Lin, 2000 Taiwan hypercholesterolaemia LPIA (Diagnostica Stago, 
France)
Antihypertensive 
medication, hormone 
replacement
59.8 (7.1) 8 wk Fluvastatin (40mg) 23 0.38 (0.31) 0.28 (0.19) Significant reduction Exclusion of familial 
hypercholesterolaemia
Lin, 2006 Taiwan hyperlipidaemia LPIA (Diagnostica Stago, 
France)
‐ 58.5 (9.7) 16 wk Simvastatin (20mg‐40mg) 22 0.33 (0.17) 0.29 (0.14) No effect  
Seljeflot, 2002 Norway dyslipidaemia and history 
of angina pectoris
ELISA in plasma and serum 
(Asserachrom D‐Di; Stago 
Diagnostica, Asnières‐sur‐
Seine, France)
Antihypertensive medi-
cation, warfarin, ASA, 
nitrates
Not reported 12 mos a) atorvastatin (20‐40mg) 
b) Simvastatin (20‐40mg)
28 
30
0.493 (0.296‐0.767) 
0.384(0.218‐0.657)
0.416 (0.269‐0.749) 
0.385(0.221‐0.541)
No effect Both serum and plasma D‐dimers 
reported. 
In this review, plasma D‐dimer (mostly 
used assay) reported
Trifiletti, 2003 Italy Hypercholesterolaemia ELISA (Asserachrom; 
Diagnostica Stago)
Exclusion of ASA users 55 (3) 6 mos Atorvastatin (20mg) 32 0.248 (0.055) 0.229 (0.042) No effect  
(Continues)
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correction factor,” while adjusting for differences in the po-
tency of statin type/dosage on LDL lowering.59 Following 
this concept, we visually inspected the relation of the SMD in 
D‐dimer levels against the statin correction factor and found 
no clear dose‐effect relation (Figure S1). An explanation for 
this lack of dose‐effect on D‐dimer levels could be that other 
mechanisms are involved in the anticoagulant effect of statins 
compared to the cholesterol‐dependent effects. The dose‐ef-
fect relation of statins on D‐dimers levels might therefore 
be independent of the potency of lowering LDL‐cholesterol 
levels.
Considering lower D‐dimer levels in statin users, the per-
formance of the diagnostic algorithms used for patients with 
suspected pulmonary embolism or deep vein thrombosis could 
be different for statin users. In these algorithms, a normal D‐
dimer level in combination with a low clinical probability of 
thrombosis safely excludes VTE.60,61 Most D‐dimer cut‐offs in 
these diagnostic algorithms range between 0.5 and 1.0 µg/mL, 
  Location Population D‐dimer assay
Information about use 
of co‐medication Age (years) Time of exposure Regimen (daily dose)
Participants 
(number)
D‐dimer (µg/mL) 
before exposure
D‐dimer (µg/mL) after 
exposure Conclusion Details
Wada, 1992 Japan Hypercholesterolaemia Felisa D‐dimer (Agen, Brisbane, 
Australia)
‐ 55.2 (14.6) >3 mos Pravastatin (10mg) 48 0.11 (0.06) 0.056 (0.039) Significant reduction  
Weiss, 2016 France HIV‐1–infected receiving 
c‐ART
ELISA (Asserachrom D‐Di) c‐ART 47 (41‐54) 12 wk Rosuvastatin (20 mg) 43 0.194 (0.147‐0.279) Baseline +3.7% (−18.2 
to +23.3)
No effect  
Cross‐sectional studies
Adams, 2013 USA Caucasian, African 
American, Hispanic 
and Chinese, free of 
cardiovascular diseases 
or active cancer
LPIA(Liatest D‐DI; Diagnostica 
Stago, Parsippany, NJ)
‐ 65.9 (8.7) 
61.5 (10.3)
‐ Statin users 
Nonusers
1001 
5786
Not reported 0.21 
0.23
Significant reduction Adjustment for age, sex, education, 
individual income and cardiovascular 
risk factors
Kaba, 2004 USA ≥2 months post‐myocar-
dial infarction
ELISA (American Diagnostica, 
Greenwich, CT, USA)
ASA, antihypertensive 
medication, oral 
anticoagulants
60 (12) 
58 (11)
‐ Statin users 
Nonusers
644 
401
0.487 (0.434) 
0.731 (1.2)
‐ Significant reduction  
Vidula, 2010 USA Peripheral artery disease ELISA (Asserachrom D‐Di kit; 
Diagnostica Stago, Asnières‐
sur‐Seine, France)
‐ 72.1 (7.9) 
73.0 (8.9)
  Statin users 
Nonusers
242 
337
1.1 (1.4) 
0.97 (1.4)
‐ No effect  
Walter, 2010 Germany Undergoing elective coro-
nary angiography
ELISA (Asserachrom D‐Di, 
Stago, Asnières, France)
Antihypertensive 
medication, oral anti-
hyperglycaemic drugs, 
ASA, clopidogrel
60.6 (10.4) 
62.4 (9.0)
‐ Atorvastatin (10‐40mg) 
Nonusers
54 
54
0.466 (0.173) 
0.454 (0.182)
‐ No effect Matching based on the cholesterol levels
Note: Data are reported as means (SD) or medians (75th percentile to 25th percentile) unless stated otherwise
Abbreviations: ASA, acetylsalicylic acid; d, days; ELISA, enzyme‐linked immunosorbent assay; LPIA, latex‐enhanced photometric immunoassays; mg, milligram;  
mos, months; NA, not available; RCT, randomized controlled trial; wk, weeks.
aOriginal data on effects on D‐dimers received and reported. 
T A B L E  1  (Continued)
F I G U R E  2  Graphical display for QUADAS‐2 results of the 22 studies included
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depending on the clinical rule applied.61,62 These cut‐off lev-
els have high sensitivity rates, and therefore, a false negative 
test in statin users is unlikely to occur. In a recent retrospective 
post hoc analysis, adjusting D‐dimer cut‐offs for statin users 
did not result in a safer diagnostic strategy.63 However, further 
validation in a larger prospective cohort is needed.
It is important to note that there are main differences 
between our methodology and the systematic review and 
  Location Population D‐dimer assay
Information about use 
of co‐medication Age (years) Time of exposure Regimen (daily dose)
Participants 
(number)
D‐dimer (µg/mL) 
before exposure
D‐dimer (µg/mL) after 
exposure Conclusion Details
Wada, 1992 Japan Hypercholesterolaemia Felisa D‐dimer (Agen, Brisbane, 
Australia)
‐ 55.2 (14.6) >3 mos Pravastatin (10mg) 48 0.11 (0.06) 0.056 (0.039) Significant reduction  
Weiss, 2016 France HIV‐1–infected receiving 
c‐ART
ELISA (Asserachrom D‐Di) c‐ART 47 (41‐54) 12 wk Rosuvastatin (20 mg) 43 0.194 (0.147‐0.279) Baseline +3.7% (−18.2 
to +23.3)
No effect  
Cross‐sectional studies
Adams, 2013 USA Caucasian, African 
American, Hispanic 
and Chinese, free of 
cardiovascular diseases 
or active cancer
LPIA(Liatest D‐DI; Diagnostica 
Stago, Parsippany, NJ)
‐ 65.9 (8.7) 
61.5 (10.3)
‐ Statin users 
Nonusers
1001 
5786
Not reported 0.21 
0.23
Significant reduction Adjustment for age, sex, education, 
individual income and cardiovascular 
risk factors
Kaba, 2004 USA ≥2 months post‐myocar-
dial infarction
ELISA (American Diagnostica, 
Greenwich, CT, USA)
ASA, antihypertensive 
medication, oral 
anticoagulants
60 (12) 
58 (11)
‐ Statin users 
Nonusers
644 
401
0.487 (0.434) 
0.731 (1.2)
‐ Significant reduction  
Vidula, 2010 USA Peripheral artery disease ELISA (Asserachrom D‐Di kit; 
Diagnostica Stago, Asnières‐
sur‐Seine, France)
‐ 72.1 (7.9) 
73.0 (8.9)
  Statin users 
Nonusers
242 
337
1.1 (1.4) 
0.97 (1.4)
‐ No effect  
Walter, 2010 Germany Undergoing elective coro-
nary angiography
ELISA (Asserachrom D‐Di, 
Stago, Asnières, France)
Antihypertensive 
medication, oral anti-
hyperglycaemic drugs, 
ASA, clopidogrel
60.6 (10.4) 
62.4 (9.0)
‐ Atorvastatin (10‐40mg) 
Nonusers
54 
54
0.466 (0.173) 
0.454 (0.182)
‐ No effect Matching based on the cholesterol levels
Note: Data are reported as means (SD) or medians (75th percentile to 25th percentile) unless stated otherwise
Abbreviations: ASA, acetylsalicylic acid; d, days; ELISA, enzyme‐linked immunosorbent assay; LPIA, latex‐enhanced photometric immunoassays; mg, milligram;  
mos, months; NA, not available; RCT, randomized controlled trial; wk, weeks.
aOriginal data on effects on D‐dimers received and reported. 
T A B L E  1  (Continued)
F I G U R E  3  Forest plot for the effect of statin therapy on plasma D‐dimer concentrations. Effect sizes were expressed as standardized mean 
difference (SMD) with its corresponding 95% confidence intervals (CIs) using Cohen's d as the summary statistic. A random‐effects model was 
used for performance of the meta‐analysis
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meta‐analysis by Sahebkar et al (2). First, in both studies 
effect sizes are expressed as standardized mean difference 
(SMD) using Cohen's d. However, Cohen's d is a dimen-
sionless quantity, calculated as the ratio of the difference be-
tween the means of two samples and their pooled standard 
deviation. Thus, Cohen's d can be interpreted as a standard-
ized difference.64 Cohen's d was developed to compare ef-
fects across studies (even) when outcome variables vary, 
and results could be interpreted by referring to benchmarks 
with small (Cohen's d = 0.2), medium (0.5) and large (0.8) 
F I G U R E  4  Leave‐one‐out sensitivity analysis of the effect of statin therapy on D‐dimer
F I G U R E  5  Forest plot of the effect of statin therapy on D‐dimer with treatment durations of < 12 weeks (above) and > 12 weeks (below). 
Effect sizes were expressed as standardized mean difference (SMD) with its corresponding 95% confidence intervals (CIs) using Cohen's d as the 
summary statistic. A random‐effects model was used for performance of the meta‐analysis
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effect sizes.25,64 Effect sizes should also be set in clinical 
perspective, incorporating that small effects could have large 
implications in clinical settings. In the article by Sahebkar 
et al therefore, the overall effect of statins on the plasma D‐
dimer levels could have been interpreted as a large effect 
(d  =  −0.988), but not as a reduction of D‐dimer levels by 
F I G U R E  6  Forest plot for the post hoc analysis on the effect of type of statin therapy on plasma D‐dimer concentrations with lipophilic 
statins above and hydrophilic statins below. Effect sizes were expressed as standardized mean difference (SMD) with its corresponding 95% 
confidence intervals (CIs) using Cohen's d as the summary statistic. A random‐effects model was used for performance of the meta‐analysis
F I G U R E  7  Funnel plot representing publication bias within literature analysed with Duval and Tweedie's trim‐and‐fill method about the 
effect of statin therapy on D‐dimer levels. Observed studies are shown as open circles, and imputed studies are shown as filled circles
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0.988  µg/mL (which would be an extremely large effect). 
Second, in the meta‐analysis by Sahebkar et al we found in-
consistencies in data extracted from the incorporated studies 
(Table S2). In seven of the nine studies, differences in mean 
(standard deviation [SD]) D‐dimer levels were reported in-
correctly in Table 1 of their meta‐analysis.12 For example, 
in both studies of Sommeijer et al and Walter et al, D‐dimer 
values after treatment were reported as D‐dimer changes.26,31 
Third, in our meta‐analysis we explained essential assump-
tions with respect to the interpretation of the original data. 
In the meta‐analysis by Sahebkar et al on the other side, it 
remains unclear how exactly means or SDs were estimated 
if not reported in the study manuscripts. Because of con-
cerns on the validity of the reported D‐dimer results, due to 
inconsistent calculation of D‐dimer changes, results of sen-
sitivity analyses and unstandardized D‐dimer measurement, 
one could argue about inclusion of the studies of Dangas et 
al, Min et al and Undas et al.65-67 In our meta‐analysis, we 
excluded these three studies.
The results of our meta‐analysis should of course also be 
interpreted with caution. In this meta‐analysis, we did not only 
include randomized controlled trials, but also cohort and cross‐
sectional studies. In the two latter types of studies, we scored 
the risk of bias to be high and heterogeneity between individ-
ual studies will be higher. The meta‐analysis was not limited 
to randomized controlled trials only, because we would then 
have ignored a large number of observational evidence.68 It is 
however important to note that within the group of cross‐sec-
tional studies, there are some differences in the retrieved data. 
The study of Adams adjusted results of D‐dimer levels in sta-
tin users and nonusers for the following potential confounding 
factors: age, sex, education, individual income, race, smoking 
status, current alcohol use, body mass index, diabetes status, 
hypertension, use of acetylsalicylic acid and hormone therapy 
use among women.46 On the other hand, Walter et al matched 
users of atorvastatin with controls according to their total cho-
lesterol levels and Kaba et al and Vidula et al did not adjust 
D‐dimer levels for any confounding factors.28,31,35 However, 
age and sex, two of the most influencing confounding fac-
tors, were not significantly different among statin users and 
nonusers in these studies. Also, duration of statin treatment 
was not assessed in these cross‐sectional data. The described 
between‐study heterogeneity is unlikely to have had a large 
impact on the results of our meta‐analysis. In the subanalyses 
of the 6 controlled trials with low risk of patient selection and 
the 16 studies with low risk of limited patient applicability, 
change in D‐dimer levels was not significantly different from 
the overall effect with all studies included. Also, a separate 
subanalysis only including the controlled trials did not differ 
from these results and resulted in lower D‐dimer values after 
statin treatment. Moreover, the post hoc analyses on treatment 
duration and statin type did not show a difference. Another 
concern might be that the included studies were heterogeneous 
in the characteristics of study participants. Studies were per-
formed in patients with proven cardiovascular disease, HIV 
infection, type 2 diabetes mellitus, lupus and COPD and in 
heart transplant patients. All these conditions could have in-
fluenced D‐dimer levels. By running our meta‐analysis with 
a random‐effects model, we assumed the studies to be hetero-
geneous and our sensitivity analysis was robust. Furthermore, 
we could not fully exclude that publication bias has had an 
effect on the results of the meta‐analysis. The adjusted effect 
size using the trim‐and‐fill method though was even larger 
than what we had observed, indicating that the effect size of 
reduction of D‐dimer levels in statin users is more likely to 
be an underestimation rather than nonsignificant. Also, Begg's 
rank correlation and Egger's test were nonsignificant, indicat-
ing no publication bias and many missing studies (n = 422) 
would be needed and imputed in our meta‐analysis to come to 
a nonsignificant effect.
In conclusion, in this meta‐analysis use of statins was as-
sociated with a reduction of D‐dimer levels, independent of 
treatment duration and type of statin used. This antithrom-
botic effect is part of the “pleiotropic” effects of statins and 
contributes to the benefits of statins on cardiovascular out-
comes. The reduction of D‐dimer levels in statin users may 
affect the performance of diagnostic algorithms on suspected 
VTE in this specific patient group, and prospective studies 
investigating the impact of statin use on these diagnostic al-
gorithms are recommended.
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